Sentence examples for bleeding frequency from inspiring English sources

In patients with haemophilia A, factor VIII (FVIII) prophylaxis reduces bleeding frequency and joint damage compared with on-demand therapy.

During treatment-free follow-up (n = 34), the reduction in pelvic pain persisted, while bleeding frequency and intensity returned to normal patterns.

Factor VIII PK parameters were significantly influenced by patient endogenous VWF Ag levels which manifested clinically by the corresponding effect on bleeding frequency.

Compared with patients treated on demand, those receiving FVIII prophylaxis have reduced bleeding frequency, rarely develop chronic arthropathy and have improved quality of life (QoL) [ 2– 7].

However, the sensitivity analyses performed showed that the results were sensitive to the unit cost of clotting FVIII, bleeding frequency, and the discount rate.

The abnormal uterine bleeding frequency differences in two different age groups (30 39 and 40 45 years old) were statistically significant (p = 0.0176).

A 100% increase in apixaban exposure is expected to raise bleeding frequencies to 7.25% (TKR) and 10.9% (THR), whereas a 200% increase would raise them to 8.49 and 12.7%.

Predicted bleeding frequencies for TKR and THR populations at risk for high apixaban exposure (female, age > 75 years, calculated creatinine clearance (cCrCL) < 30 ml/min, body weight < 50 kg) (6.85 and 10.3%, respectively) were comparable to the reference population (male/female, age 65−75 years, cCrCL ≥ 80 ml/min, body weight 65−85 kg) (6.18 and 9.32%, respectively).

Frequent recurrence of bleeding, however, precludes the reinstatement of a baseline level of motion, strength, and physical appearance; inadequate resolution of trauma arising from such events can in turn exacerbate bleed frequency.

Prophylaxis regimens initiated at a young age (≤4 years of age) are shown to reduce bleed frequency and joint deterioration later into adulthood [5], and are therefore considered the benchmark in care for severe haemophilia [2].

Approaches to minimising the long-term risk of joint damage and deterioration among these patients – beginning at a young age with proactive therapy protocols to minimise bleed frequency and severity – will serve to reduce future burdens on hospital systems and are a justification for continued access to preventative therapy protocols.